Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | GLS | O94925 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MIF | P14174 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15945774 | 1.00 | ACHE (0.55) | ACHECYP1A2CYP2C9CYP2C19GLS | |
| SCHEMBL31348131 | 1.00 | ACHE (0.55) | ACHECYP1A2CYP2C9CYP2C19GLS | |
| SCHEMBL1905981 | 1.00 | ACHE (0.55) | ACHECYP1A2CYP2C9CYP2C19GLS | |
| SCHEMBL571018 | 0.90 | CYP1A2 (0.56) | ACHECYP1A2CYP2C9CYP2C19MIF | |
| SCHEMBL8061487 | 0.88 | TDP1 (0.51) | CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17983202 | 0.87 | ACHE (0.43) | ACHECYP1A2CYP2C9CYP2C19GLS | |
| SCHEMBL8070914 | 0.87 | TDP1 (0.54) | CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL8071862 | 0.87 | TDP1 (0.54) | CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4495927 | 0.85 | HEXA (0.58) | CYP1A2NPSR1SMN1; SMN2RAB9A | |
| SCHEMBL38819 | 0.81 | CYP2C9 (0.68) | ACHECYP1A2CYP2C9CYP2C19GLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3848351-B1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | US HEALTH (US) | 2025-01-15 | — | — | EP | disclosed |
| US-20240408084-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-12-12 | — | — | US | disclosed |
| US-12162861-B2 | Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-12-10 | — | — | US | disclosed |
| US-12097196-B2 | Dopamine D3 receptor selective antagonists/partial agonists and uses thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-09-24 | — | — | US | disclosed |
| US-20220265643-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2022-08-25 | — | — | US | disclosed |
| US-20220185798-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2022-06-16 | — | — | US | disclosed |
| US-20220185798-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2022-06-16 | — | — | US | disclosed |
| US-11337971-B2 | Dopamine D3 receptor selective antagonists/partial agonists and uses thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-05-24 | — | — | US | disclosed |
| US-11337971-B2 | Dopamine D3 receptor selective antagonists/partial agonists and uses thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-05-24 | — | — | US | disclosed |
| US-11299476-B2 | Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-04-12 | — | — | US | disclosed |
| EP-3849963-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF | The United States of America, as Represented By the Secretary, Department of Health and Human Services (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-3848351-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2021-07-14 | — | — | EP | disclosed |
| EP-3429993-B1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | US HEALTH (US) | 2021-05-26 | — | — | EP | disclosed |
| US-20200291000-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2020-09-17 | — | — | US | disclosed |
| US-20200291000-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2020-09-17 | — | — | US | disclosed |
| WO-2020055725-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-03-19 | — | — | WO | disclosed |
| EP-3429993-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2019-01-23 | — | — | EP | disclosed |
| WO-2017160552-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-09-21 | — | — | WO | disclosed |
| US-9290503-B2 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2016-03-22 | — | — | US | disclosed |
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | CHEMBRIDGE CORPORATION (US) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228350-A1 | TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS | MALT1, TPMT, TSLP | ACHE 3905/4885CYP1A2 1089/4885CYP2C9 1806/4885 |
| US-20220185798-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | DRD3, DRD2, SLC6A3 | ACHE 1090/4885CYP1A2 1308/4885CYP2C9 2366/4885 |
| US-12162861-B2 | Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof | DRD3, DRD2, SLC6A3 | ACHE 1090/4885CYP1A2 1308/4885CYP2C9 2366/4885 |
| US-20200291000-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF | DRD3, DRD2, SLC6A3 | ACHE 1090/4885CYP1A2 1308/4885CYP2C9 2366/4885 |
| US-12097196-B2 | Dopamine D3 receptor selective antagonists/partial agonists and uses thereof | OPRD1, OPRK1, DRD3 | ACHE 374/4885CYP1A2 455/4885CYP2C9 930/4885 |
| US-11299476-B2 | Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof | DRD3, DRD2, SLC6A3 | ACHE 1090/4885CYP1A2 1308/4885CYP2C9 2366/4885 |
| US-20240408084-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF | DRD3, OPRD1, DRD2 | ACHE 1054/4885CYP1A2 619/4885CYP2C9 1625/4885 |
| US-20220265643-A1 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF | OPRD1, OPRK1, DRD3 | ACHE 374/4885CYP1A2 455/4885CYP2C9 930/4885 |
| US-11337971-B2 | Dopamine D3 receptor selective antagonists/partial agonists and uses thereof | OPRD1, OPRK1, DRD3 | ACHE 374/4885CYP1A2 455/4885CYP2C9 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.